## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Youngman et al.

International Application No.: PCT/US03/39975

International Filing Date: December 12, 2003

For: Indane Compounds as CCR5 Antagonists


Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Patty Wilson

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97 [ ] Copies of the references are enclosed [ ] Copies of the references were submitted in parent application Serial No. (37 CFR 1.98(d)) [X] A copy of the International Search Report which issued on International Application No. PCT/US03/39975 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau. The Information Disclosure Statement submitted herewith is being filed within three A. [X] months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b). OR The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)). The Information Disclosure Statement transmitted herewith is being filed after three months B. [] of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: a final action under § 1.113 or **(1)** a notice of allowance under § 1.311, (2) whichever occurs first. Express Mail Label No.: EV33: Date of Mailing:  $\frac{(Q/9/oS)^2}{2}$ I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

## Atty. Docket No. PY496445w



- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. [] The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [ ] The petition fee set forth in  $\S 1.17(i)(1)$  (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

Bonnie L. Deppenbrock
Attorney of Record

Attorney of Record Registration No. 28,209

Date: 7 June 2005 Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1577 Facsimile: (919) 483-7988

JC17 Rec'd PCT/PTO 09 JUN 2005 of 1

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					SERIAL NO. FILING DATE APPLICANT GROUP		Youngman et al.		
IIS PATEN					ATTORNEY DOCKET NO. ENT DOCUMENTS		PU4963USw		
Examiner Initials		Patent Number	Issue Date	Name  Mitsuru et al.		Class	Subclass	Filing Date If Appropriate	
	1.	6,096,780	8/1/2000						
	1.	0,090,780	8/1/2000	Witsurae	t al.	<del></del>			
	<del>                                     </del>			<del>                                     </del>			<del></del>		
	<u> </u>		<u> </u>	<u> </u>					
				Continue on p		20			
	Г	Document		N PAIEN.	T DOCUMENT	<u>s</u>	• •	Translation	
		Number	Publication Date		Country	Class	Subclass	Yes   No	
	2.	WO 04/09584	1/29/2004	PCT	Sountry	Caus	Bubblass		
· · · · ·									
					·				
	ļ								
	<del> </del>					<del></del>			
-	<del>                                     </del>		<del> </del>			1		· · · · · ·	
	· · · · · ·			Continue on p	oage				
		OTHER DOCU	MENTS (Includ	ing Author,	Title, Journal-	Date, Page Numb	er, Etc.)		
								·	
				-					
	<del></del>								
		-							
								-	
					· · · · · ·				
				Oamain					
	•			Continue on	page	DATEC	ONSIDERE	D	
	EXAMINER					DATE CONSIDERED			